Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Yutang Huang"'
Autor:
Xiaoqing Wang, Ju Zhu, Lingling Li, Qilin Zhao, Yutang Huang, Chunjie Wen, Dan Chen, Lanxiang Wu
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-16 (2024)
Abstract Background Patient-derived xenograft (PDX) is currently considered a preferred preclinical model to evaluate drug sensitivity, explore drug resistance mechanisms, and select individualized treatment regimens. Methods Histopathological examin
Externí odkaz:
https://doaj.org/article/0d7cbfbfabc24a318b9e68dfc9b72d47
Publikováno v:
MedComm, Vol 5, Iss 8, Pp n/a-n/a (2024)
Abstract Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in lung adenocarcinoma (LUAD), but the underlying mechanisms are still not fully understood. Cancer‐associated fibroblasts (CAFs) are the most abundant stro
Externí odkaz:
https://doaj.org/article/2df4f14e2be14d66a2ad6ce4316b5dfb
Autor:
Yutang Huang, Yan Du, Yujie Zheng, Chunjie Wen, Hecun Zou, Jiafeng Huang, Honghao Zhou, Hongbo Zhao, Lanxiang Wu
Publikováno v:
Cell Death and Disease, Vol 13, Iss 6, Pp 1-13 (2022)
Abstract High-grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy mainly due to its extensive metastasis. Cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3), a newly discovered splice variant of solute carri
Externí odkaz:
https://doaj.org/article/457d49e446264a439226745587228e70
Autor:
Yutang Huang, Yi Dai, Chunjie Wen, Shuai He, Jingjing Shi, Dezhang Zhao, Lanxiang Wu, Honghao Zhou
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 885-899 (2020)
Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated t
Externí odkaz:
https://doaj.org/article/80943fd001944ea0bb59de80397dfcf8
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable devel
Externí odkaz:
https://doaj.org/article/91dbb84534d74748be425f0d1b3bae92
Publikováno v:
Molecular Omics. 19:238-251
Lnc-TMEM132D-AS1 induces acquired resistance to osimertinib in NSCLC by the miR-766-5p/ENTPD1 axis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e10a18b24693169512a6b7c16175236a
https://doi.org/10.1039/d2mo00261b
https://doi.org/10.1039/d2mo00261b
Autor:
Chunjie Wen, Yaji Li, Yutang Huang, Nan Wang, Shuai He, Meihua Bao, Honghao Zhou, Lanxiang Wu
Publikováno v:
The international journal of biochemistrycell biology. 154
Gefitinib is the first-line treatment for non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutation. However, acquired resistance significantly limits its therapeutic efficacy. CircSETD3 has been reported to promote gefitinib resistance in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ef77e4f3232c8f692662005b8d5d7e
https://pubmed.ncbi.nlm.nih.gov/36503048
https://pubmed.ncbi.nlm.nih.gov/36503048
Objective: Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in non-small-cell lung cancer (NSCLC). Current knowledge about the role of long non-coding RNAs (lncRNAs) in this phenomenon is insufficient. Here, we aim t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf244225f05f4c99e206454cec466d79
https://doi.org/10.21203/rs.3.rs-1747227/v1
https://doi.org/10.21203/rs.3.rs-1747227/v1
Autor:
Hong-Hao Zhou, Shuai He, Lan-Xiang Wu, Yi Dai, Dezhang Zhao, Chunjie Wen, Yutang Huang, Jingjing Shi
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 885-899 (2020)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575fa86a02e644d7d5abe2f1539997e9
https://doi.org/10.1016/j.omtn.2020.07.027
https://doi.org/10.1016/j.omtn.2020.07.027